Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Autoimmune Diseases
Pharma
RemeGen's telitacicept result sets up IgAN submission in China
For the second time in two weeks, RemeGen and Vor Bio have reported a phase 3 win for telitacicept, this time in IgA nephropathy.
Kevin Dunleavy
Aug 27, 2025 11:13am
Argenx pursues Vyvgart nod in seronegative myasthenia gravis
Aug 25, 2025 11:38am
Lawsuit points to alleged misconduct at Amgen-bought biotech
Jul 25, 2025 11:18am
China biotech deals, Takeda, LaNova—Fierce Pharma Asia
Jul 18, 2025 9:04am
FDA flags ‘severe worsening’ of disease for argenx's Vyvgart SC
Jul 1, 2025 11:19am
RemeGen, Harbour, Datroway—Fierce Pharma Asia
Jun 27, 2025 8:37am
